Literature DB >> 22430364

Assessment and modulation of forsythiaside absorption with MDCKII cells and validation with in situ intestinal experiment.

Yun-Xia Li1, Ruo-Qi Zhang, Cheng Peng.   

Abstract

Forsythiaside was characterized by low intestinal absorption by in situ rat experiment and Caco-2 cells. The mechanisms behind this low absorption had not yet been elucidated. The purpose of this study was to investigate the role of efflux transporters in the intestinal absorption of forsythiaside as a potential mechanism for its low small-intestinal absorption following oral administration. Polarized MDCKII cell lines stably transfected with human or murine complementary DNA encoding for various efflux transporters (P-gp/MDR1, MRP2 and Bcrp1) were used to study transepithelial transport of forsythiaside and compare results with the MDCKII-Wild type cells. The transportation inhibitors GF120918, MK571 and Ko143 were used to investigate the transport mechanism. The active transport of forsythiaside was found in MDCKII-WT cells. The MDCKII-MRP2 and MDCKII-Bcrp1 cells significantly increased forsythiaside efflux ratio compared with the parental cells due to the apically directed transport by MRP2 and Bcrp1, respectively. The efflux ratios in MRP2 and Bcrp1 transfected cell lines were greatly decreased in the presence of MK-571 and Ko143, respectively, which indicated that forsythiaside efflux by MRP2 and Bcrp1 were significantly inhibited by their selective inhibitors. MDCKII-MDR1 cells did not exhibit a significant reduction in the forsythiaside efflux compared with the parental cells, indicating that it was not a good substrate for MDR1. And the results were then validated by the in situ experiment. This study presents direct evidence that forsythiaside is effluxed by both MRP2 and Bcrp1, which may contribute to its poor oral bioavailability.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22430364     DOI: 10.1007/s13318-012-0088-7

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  29 in total

Review 1.  Gastrointestinal absorption of drugs: methods and studies.

Authors:  L Barthe; J Woodley; G Houin
Journal:  Fundam Clin Pharmacol       Date:  1999       Impact factor: 2.748

Review 2.  ABC transporters involved in the transport of plant secondary metabolites.

Authors:  Kazufumi Yazaki
Journal:  FEBS Lett       Date:  2005-12-12       Impact factor: 4.124

3.  Investigation on the absorption of phillyrin and forsythiaside in rat digestive tract.

Authors:  Yun-xia Li; Cheng Peng; Liang-hong Ye; Ruo-Qi Zhang; Xue-hua Jiang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-03-09       Impact factor: 2.441

4.  Intestinal drug absorption and metabolism. I. Comparison of methods and models to study physiological factors of in vitro and in vivo intestinal absorption.

Authors:  W H Barr; S Riegelman
Journal:  J Pharm Sci       Date:  1970-02       Impact factor: 3.534

5.  [Antibacterial constituents of the unripe fruit of Forsythia suspensa (Thunb.) Vahl].

Authors:  H X Kuang; N Zhang; Z B Lu
Journal:  Zhong Yao Tong Bao       Date:  1988-07

Review 6.  Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.

Authors:  Pauline Breedveld; Jos H Beijnen; Jan H M Schellens
Journal:  Trends Pharmacol Sci       Date:  2005-12-05       Impact factor: 14.819

7.  Mucus as a barrier to the permeability of hydrophilic and lipophilic compounds in the absence and presence of sodium taurocholate micellar systems using cell culture models.

Authors:  C Meaney; C O'Driscoll
Journal:  Eur J Pharm Sci       Date:  1999-07       Impact factor: 4.384

8.  A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.

Authors:  G L Amidon; H Lennernäs; V P Shah; J R Crison
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

9.  Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs.

Authors:  Pär Matsson; Jenny M Pedersen; Ulf Norinder; Christel A S Bergström; Per Artursson
Journal:  Pharm Res       Date:  2009-05-07       Impact factor: 4.200

10.  Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

Authors:  C M F Kruijtzer; J H Beijnen; H Rosing; W W ten Bokkel Huinink; M Schot; R C Jewell; E M Paul; J H M Schellens
Journal:  J Clin Oncol       Date:  2002-07-01       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.